Moderna (MRNA) shares have been under pressure lately, slipping around 8% over the past month. Investors continue to weigh up ...

Moderna stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return.

Moderna stock is trading sharply lower Monday afternoon as recent clinical setbacks overshadowed positive pipeline news.

Moderna, Inc. (MRNA) is a biotechnology firm based in Cambridge, Massachusetts, that focuses on mRNA technology to create ...

Moderna beat analysts’ revenue expectations by 10.7% last quarter, reporting revenues of $142 million, down 41.1% year on ...

Moderna stock surged Thursday after the Covid vaccine-maker significantly cut its third-quarter costs, and still managed to ...

Q3 earnings beat estimates but pipeline setback and lower 2025 guidance raise concerns. Full analysis of results and outlook.

For the quarter ended September 2025, Moderna (MRNA) reported revenue of $1.02 billion, down 45.4% over the same period last ...

As you might know, Moderna, Inc. (NASDAQ:MRNA) just kicked off its latest quarterly results with some very strong numbers.

Get the latest insights from Moderna's Q3 2025 earnings call: revenue guidance updates, cost reduction highlights, and pipeline progress.

July 31 (Reuters) - Moderna (MRNA.O), opens new tab said on Thursday it would trim roughly 10% of its global workforce and have fewer than 5,000 employees by the end of the year, as the biotech ...

Moderna posted a smaller-than-expected quarterly loss and reduced its annual operating expenses outlook by $700 million on Thursday, helped by lower production costs and a cutback in research and ...